LipoScience, which provides a proprietary diagnostic test for assessing and monitoring a person's risk of heart disease, submitted an IPO filing on Friday with the SEC. The Company developed its proprietary product, which began shipping in 1999, using nuclear magnetic resonance, or NMR, spectroscopy technology. In 2001, LipoScience booked more than $18 million in revenues, up from just $6 million in 2000. Merrill Lynch, US Bancorp Piper Jaffray, Thomas Weisel and Pacific Growth Equities were selected as the underwriting team. Terms for the IPO have yet to be announced.
